ALLER-NIL/5mL

ALLER-NIL

Pack : 5ml Pack

DESCRIPTION:

Allernil- Eye Drops (Cromolyn Sodium Ophthalmic Solution) is an anti-inflammatory medication used to treat allergysymptoms that affect the eyes, such as itching, burning, watering, swelling, redness, or sensitivity to light. Opticrom is available in generic form. Common side effects of Opticrom include burning or stinging of the eye after you use the eye drops, dry or irritated eyes, puffy eyes, or watery eyes.

COMPOSITION:

Label Claim: Each ML Contains :

• Cromolyn Sodium USP...........20 mg
• Benzalkonium Chloride Solution USP......0.1mg
• Aqueous Buffered Vehicle...........q.s.

PACKAGING

Primary packing - 5ml Opaque poly bottles White caps & Nozzles.

Secondary Packing - Labels, Cartons, Shrink Pack & Shipper box.

AVAILABILITY

5ml of solution in White poly bottles with white caps & nozzles in properly sealed.

SHELF LIFE:

24 months from the date of manufacturing.

STORAGE:

Keep in a cool & dark place. Below 30ºC.Do not allow to Freeze.

CLINICAL PHARMACOLOGY:

In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell.

Another activity demonstrated in vitro is the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.

Cromolyn sodium has no intrinsic vasoconstrictor, antihistaminic or anti-inflammatory activity.Cromolyn sodium is poorly absorbed. When multiple doses of cromolyn sodium ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of cromolyn sodium is absorbed into the systemic circulation (presumably by way of the eye, nasal passages, buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the cromolyn sodium dose penetrate into the aqueous humor and clearance from this chamber is virtually complete within 24 hours after treatment is stopped.

In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of cromolyn sodium is absorbed following administration to the eye.

INDICATIONS AND USAGE:

Allernil- Eye Drops (Cromolyn Sodium Ophthalmic Solution) is is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

CONTRAINDICATIONS:

Allernil- Eye Drops (Cromolyn Sodium Ophthalmic Solution) is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.

WARNINGS :

Allernil- Eye Drops (Cromolyn Sodium Ophthalmic Solution) is for topical use only and not for injection or oral use.

DOSAGE AND ADMINISTRATION:

The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium.

Patients should be advised that the effect of cromolyn sodium ophthalmic solution therapy is dependent upon its administration at regular intervals, as directed.

Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.

If required, corticosteroids may be used concomitantly with Allernil- Eye Drops (Cromolyn Sodium Ophthalmic Solution).

SUPPLY:

Allernil- Eye Drops is supplied in one clear polethylene Bottle packed with printed labelled & cartons And Such 25 Carton Packed in a Shrink Sleeves & corrugated box.

Aod address

ALLERNIL-O

ALLERNIL-O

Pack : 5ml Pack

DESCRIPTION:

Allernil-O Eye Drops (Olopatadine Hydrochloride Ophthalmic Solution) is a sterile ophthalmic solution containing olopatadine, a relatively selective H1-receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes.

COMPOSITION:

Label Claim: Each ML Contains :

Olopatadine Hydrochloride IP

  • Equivalent to Olopatadine......... 0.1% w/v
  • Benzalkonium Chloride Solution IP.........0.01%w/v
  • Sterile aqueous Vehicle..........q.s.Sterile aqueous Vehicle..........q.s.

PACKAGING:

Primary packing - 5ml Opaque poly bottles White caps & Nozzles.

Secondary Packing - Labels, Cartons, Shrink Pack & Shipper box.

AVAILABILITY:

5ml of solution in White poly bottles with white caps & nozzles in properly sealed.

SHELF LIFE:

24 months from the date of manufacturing.

STORAGE:

Keep in a cool & dark place. Below 30ºC.Do not allow to Freeze.

CLINICAL PHARMACOLOGY:

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H1-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.
Results from an environmental study demonstrated that Allernil-O Eye Drops (Olopatadine Hydrochloride Ophthalmic Solution), was effective in the treatment of the signs and symptoms of allergic conjunctivitis when dosed twice daily for up to 6 weeks. Results from conjunctival antigen challenge studies demonstrated that Allernil-O Eye Drops (Olopatadine Hydrochloride Ophthalmic Solution), when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

INDICATIONS AND USAGE:

Allernil-O Eye Drops (Olopatadine Hydrochloride Ophthalmic Solution) is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

CONTRAINDICATIONS:

Allernil-O Eye Drops (Olopatadine Hydrochloride Ophthalmic Solution) is contraindicated in persons with a known hypersensitivity to Olopatadine Hydrochloride or any components of Olopatadine Hydrochloride Ophthalmic Solution.

WARNINGS :

Allernil-O Eye Drops (Olopatadine Hydrochloride Ophthalmic Solution) is for topical use only and not for injection or oral use.

DOSAGE AND ADMINISTRATION:

The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.

SUPPLY:

Allernil-O Eye Drops is supplied in one White polethylene Bottle packed with printed labelled & cartons And Such 25 Carton Packed in a Shrink Sleeves & corrugated box.

Aod address

ANC

Pack : 10ml Pack

DESCRIPTION:

ANC Eye Drops actas an anti allergic, astringent & decongestant. Naphazoline acts as a vasoconstrictor to narrow swollen blood vessels to reduce the redness.
Hydrxtpropylmethyl
cellulose acts as lubricant to give relief from dry irritated eyes.
Chlorpheniramine maleate acts as antiallergic gives relief from itching, watering of eyes due to allergy
.Zinc sulphate acts as an astringent that helps clear mucus from the outer surface of the eye often associated with exposure to pollen, dust and smoke.

COMPOSITION:

Label Claim: Each ML Contains :

• Naphazoline Hcl USP .............. 0.56 mg
• Chlorpheniramine Maleate IP............0.1mg
• Zinc Sulphate IP..................1.2 mg
• Hypromellose IP ................2 mg
• Benzalkonium Chloride Solution IP..........0.0001ml (as preservative)
• Sterile Aqueous vehicle............q.s.

PACKAGING

Primary packing - 10ml Opaque poly bottles White caps & Nozzles.
Secondary Packing - Labels, Cartons, Shrink Pack & Shipper box.

AVAILABILITY

10ml of solution in White poly bottles with white caps & nozzles in properly sealed.

SHELF LIFE:

24 months from the date of manufacturing.

STORAGE:

Keep in a cool & dark place. Below 30ºC.Do not allow to Freeze.

INDICATIONS :

It is indicated for temporary relief of redness and discomfort due to minor eye irritations and relief of burning and irritations due to dryness of the eye.

DOSAGE & ADMINISTRATION:

Instill one or two drops in the affected eye(s) 3 times a day.

CONTRAINDICATIONS:

It is contraindicated in patients with known history of hypersensitivity to the ingredients used in this formulation.

WARNING AND PRECAUTIONS:

To avoid contamination do not touch tip of container to any surface. Replace cap after using. If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the conditions worsens or persists for more than 72 hours, discontinue use and consult a doctor. Keep this and all drugs out of reach of children.

SUPPLY:

ANC Eye Drops is supplied in 10ml clear poly bottles packed with printed labeled in a unit carton and, Such 25 Carton packed in a shrink sleeves.such,12 shrinks packed in a shipper.

Aod address

ANC

ALLERNIL-HS

ALLERNIL-HS Eye Drops

(Olopatadine Ophthalmic Solution IP)

DESCRIPTION:

ALLERNIL-HS Eye Drops (Olopatadine Ophthalmic Solution IP) is a sterile ophthalmic solution containing olopatadine, a relatively selective H1-receptor antagonist and inhibitor ofhistamine release from the mast cell,for topical administration to the eyes.

COMPOSITION:

Each ML Contains :

• Olopatadine Hydrochloride
• eq. to Olopatadine U.S.P.                            0.2mg
• Benzalkonium Chloride Solution I.P.          0.1mg
  (As preservative)
• Sterile Aqueous Vehicle.                              q. s..

CLINICAL  PHARMACOLOGY

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamineH1-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers(totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.

Results from an environmental study demonstrated that ALLERNIL-HS Eye Drops (Olopatadine Ophthalmic Solution IP) was effective in the treatment of the signs and symptoms of allergic conjunctivitis when dosed twice daily for up to 6 weeks. Results from conjunctival antigen challenge studies demonstrated that ALLERNIL-HS Eye Drops (Olopatadine Ophthalmic Solution IP), when subjects were challenged with antigen both initially and up to 8hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

INDICATIONS AND USAGE

ALLERNIL-HS (Olopatadine Ophthalmic Solution IP) Eye Drops is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

DOSAGE AND ADMINISTRATION

The recommended dose is one drop in each affected eye twice daily at an interval of 6 to 8 hours.

CONTRAINDICATIONS

ALLERNIL-HS Eye Drops(Olopatadine Ophthalmic Solution IP) is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any component of this product.

ALLERNIL-HS Eye Drops (Olopatadine Ophthalmic Solution IP) is for topical use only and not for injection or oral use.

PRECAUTIONS

Patients should be given the following instructions to prevent contamination the dropper tip and solution, care should betaken not to touch the eyelids or surrounding areas with the dropper tip. The bottle should be kept tightly closed when not in use. if the eye is red, contact lens should not be worn.

ALLERNIL-HS (Olopatadine Ophthalmic Solution IP) Eye Drops should not be used to treat contact lens related irritation. Solution IP) Benzalkonium Chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling ALLERNIL-HS Eye Drops (Olopatadine Ophthalmic Solution IP) before they insert their contact lenses.

Pregnancy

Olopatadine was found not to be teratogenic in rats and rabbits. There are ,however, no adequate and well-controlled studies in pregnant woman. Because animal studies are not always predictive of human responses, this drug should be used in pregnant woman only if the potential benefit o the mother justifies the potential risk to the embryo or fetus. Nursing Mothers.

Olopatadine has been identified in the milk of following oral administration. it is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when ALLERNIL-HS Eye Drops(Olopatadine Ophthalmic Solution IP) is administered to a nursing mother.

Pediatric Use

safety and effectiveness of ALLERNIL-HS Eye Drops (Olopatadine Ophthalmic Solution IP)pediatric patients below the age of 3 years have not been established .

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTION

ALLERNIL - HS Eye Drops ( Olopatadine Ophthalmic Solution IP) is well tolerated Side effects reported by a minority of patients are headache, Blurred vision, burning or stinging, dry eye, foreign body sensation hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritis, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

STORAGE

Keep in a cool &dark place.Below 250C. Do not allow to Freeze.

SHELF LIFE

24 Months

HOW SUPPLIED

ALLERNIL - HS Eye Drops ( Olopatadine Ophthalmic Solution IP) is supplied in 5 mL poly bottles.

Aod address

K-FEN 0.5

K-FEN 0.5

(Olopatadine Ophthalmic Solution IP)

 THIS LEAFLET CONTAINS IMPORTANT PRODUCT USE AND SAFETY INFORMATION, PLEASE READ CAREFULLY AND RETAIN FOR FURTHER FUTURE REFERENCE.

DESCRIPTION:

K-FEN 0.5 (Ketotifen Ophthalmic Solution)is a sterile ophthalmic solution containing ketotifen for topical administration to the eyes. Ketotifen fumarate is a finely crystalline powder with an empirical formula of C23H23NO5S and a molecular weight of 425.50.

COMPOSITION:

Each ML Contains :

• Ketotifen Fumarate IP
• Eq. to Ketotifen                       0.5mg
• Benzalkonium Chloride
• Solution IP                              0.05mg
(As preservative)
• Sterile Aqueous Vehicle        q .s.

INDICATIONS AND CLINICAL USE

K-FEN 0.5 (Ketotifen Ophthalmic Solution)is indicated for :
• treatment of allergic conjunctivitis.

CONTRAINDICATIONS

• Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing ,

WARNINGS AND PRECAUTIONS

General

For topical use only. Not for injection or oral use.
As with all ophthalmic preparations containing Benzalkonium Chloride, patients are advised not to instill Ketotifen Ophthalmic Solution while wearing soft (hydrophilic) contact lenses. Wearers of soft contact lenses should be instructed to remove lenses prior to instillation of drops and to wait at least ten minutes after instilling Ketotifen Ophthalmic Solution before they insert their contact lenses. 
To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.

Special Populations

Pregnant Women: There are no clinical trials on the use of Ketotifen Ophthalmic Solution in pregnant or nursing women, therefore, Ketotifen Ophthalmic Solution should not be used during pregnancy, except if the benefit justifies the potential risk to the fetus.

Pediatrics (>3years of age):

Ketotifen Ophthalmic Solution is indicated for Use in pediatric patients over the age of 3 years.

ADVERSE REACTIONS

In controlled clinical studies with Ketotifen Ophthalmic Solution, conjunctival injection was the most common ocular adverse reaction related to therapy, with a reported incidence of 7.0%. Headache was the most common non-ocular adverse reaction related to therapy, with a reported incidence of 1.5%. The occurrence of these side effects were generally mild and did not result in discontinuation or interruption of trial medication.
The following ocular adverse reactions related to therapy were reported at an incidence of less than 3%. Itching, dry eyes, burning or stinging, eyelid disorder and discharge.

DRUG INTERACTIONS

If Ketotifen Ophthalmic Solution is used concomitantly with other eye medications, patients should be advised to wait at least 5 minutes between the medications.

DOSAGE AND ADMINISTRATION

The recommended dose is one drop in the affected eye(s) every 8 to 12 hours.

OVERDOSAGE

For management of a suspected overdose, especially accidental oral ingestion, please contact your regional poison control center.  
Oral ingestion of the contents of a 5 mL bottle would be equivalent to 1.25 mg of Ketotifen Fumarate. Clinical results have shown no serious signs or symptoms after the ingestion of up to 20 mg of Ketotifen Fumarate.

CLINICAL PHARMACOLOGY

Mechanism of Action
Ketotifen is a fast acting non-competitive histamine antagonist (H1-receptor). In addition, Ketotifen Ophthalmic Solution, Ketotifen inhibits the release of mediators from mast cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils has also been demonstrated. Additionally, Ketotifen attenuates the effects of PAF and inhibits cAMP phosphodiesterase.
In human conjunctival allergen challenge studies, Ketotifen Ophthalmic Solution was significantly more effective than placebo in preventing ocular itching and redness associated with allergic conjunctivitis. The effect was seen within minutes after administration and lasted up to 12 hours.

Pharmacodynamics                                                                                                                In human conjunctival allergen challenge studies, Ketotifen Ophthalmic Solution was significantly more effective than placebo in preventing ocular itching and redness associated with allergic conjunctivitis. The effect was seen within minutes after administration and lasted up to 12 hours. In a placebo-controlled clinical study designed to evaluate safety, Ketotifen Ophthalmic Solution, administered four times a day for 6 weeks, was shown to be safe and well-tolerated in subjects aged3 years and older.
                                                                                                     

INDICATIONS AND USAGE

K-FEN 0.5 (Ketotifen Ophthalmic Solution) is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.

STORAGE

 Store in dry place at atemperature not exceeding25°C.
Do not allow to Freeze.

SHELF LIFE

24 months.

HOW SUPPLIED

K-FEN 0.5 / 5mL (Ketotifen Ophthalmic Solution) is supplied in 5mL poly bottle.

Aod address